查詢結果分析
相關文獻
- The DCC Protein Expression in Breast Carcinoma
- The Effects of Pesticides Chlordane, Dieldrin and Endosulfan on the Growth of Human Breast Cancer Cell Lines MCF-7 and SK-BR-3
- Prognostic Factors in Node-Negative Breast Cancer Patients: The Experience in Taiwan
- Cystic Hypersecretory Intraductal Carcinoma of the Breast--Case Report
- Timing of Shoulder Exercise after Modified Radical Mastectomy: A Prospective Study
- 前哨淋巴掃描診斷乳癌早期轉移
- Measurement of the Quality of Life during Different Clinical Phases of Breast Cancer
- The Prognostic Significance of Pathologic Characteristics of Breast Cancer Patients in Taiwan
- 趨勢面分析法在癌症地圖繪製上的應用: 以臺灣的乳癌死亡率為例
- 使用Tamoxifen治療乳癌
頁籤選單縮合
題 名 | The DCC Protein Expression in Breast Carcinoma=DCC蛋白在乳癌之表達 |
---|---|
作 者 | 許永祥; 蕭正光; | 書刊名 | The Kaohsiung Journal of Medical Sciences |
卷 期 | 16:5 2000.05[民89.05] |
頁 次 | 頁233-240 |
分類號 | 416.226 |
關鍵詞 | DCC蛋白; 乳癌; DCC; HER-2/neu; P53; Breast carcinoma; |
語 文 | 英文(English) |
中文摘要 | DCC基因位於第十八對染色體上,此基因不活化與大腸直腸癌之發生與 轉移有關。本研究,用免疫組織化學染色方法觀察79例侵襲性乳癌細胞內DCC 蛋白,P53及HER-2/neu之表達。DCC蛋白表達減少者有42例(52%),而HER-2/neu 及P53過度表現率分別為36.8% (29/79)及32.9% (26/79)。為了評估病人預後,病 人追蹤時間由1990年5月到1998年8月,平均追蹤52個月(4~94個月),病 人同時合併DCC陰性及HER-2/neu過度表現對乳癌預後有邊緣效應(P=0.060)。 但病人同時合併DCC陰性及P53過度表現則對乳癌預後無影響(P=0.36)。本研 究顯示同時DCC蛋白表現減少及HER-2/neu過度表現可能影響乳癌預後。 |
英文摘要 | Inactivation of the gene eleted in colon cancer?(DCC) on chromosome 18 is known to be associated with the tumorigenesis and metastasis of colorectal cancer. In the present study, we investigated the expression of DCC, P53 and HER-2/neu product in surgical specimens from 79 patients with invasive breast cancer by immunohistochemistry staining and found the expression of DCC to be decreased in 42 tumors (52%). Overexpression of HER-2/neu and P53 was detected in 29 (36.8%) and 26 (32.9%) of this 79 breast cancer specimens, respectively. To evaluate the outcomes of the 79 breast cancer patients, we followed up the patients during the period from May 1990 to August 1998. The average length of follow-up was 52 months (ranging from 4 to 94 months). Patients with tumors having a combination of DCC-negative and HER-2/neu overexpression showed a marginal influence on survival time of breast cancer (P=0.06). However, patients with tumors having a combination of DCC-neagive and P53 overexpression showed no influence of these on survival time of breast cancer (P=0.36). These findings suggest that a decreased DCC expression and HER-2/neu overexpression may influence the prognosis of breast cancer. |
本系統中英文摘要資訊取自各篇刊載內容。